Top-Rated Stocks NASDAQ:CYTK Cytokinetics - CYTK News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $35.20 -0.13 (-0.37%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$34.55▼$35.5150-Day Range$35.20▼$45.7152-Week Range$33.60▼$55.80Volume841,079 shsAverage Volume981,721 shsMarket Capitalization$3.35 billionP/E RatioN/ADividend YieldN/APrice Target$57.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.600.35▲Average Medical News Sentiment CYTK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼64▲CYTK Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePeregrine Capital Management LLC Increases Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)marketbeat.com - March 19 at 6:21 AMInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells 12,500 Shares of Stockmarketbeat.com - March 17 at 4:48 PMCytokinetics Reports Fourth Quarter 2022 Financial Resultsfinance.yahoo.com - March 20 at 8:01 AMMizuho Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)markets.businessinsider.com - March 18 at 10:58 PMFady Ibraham Malik Sells 4,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stockamericanbankingnews.com - March 11 at 6:34 AMCantor Fitzgerald Reiterates Overweight Rating for Cytokinetics (NASDAQ:CYTK)americanbankingnews.com - March 11 at 1:56 AMIndustry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 15%finance.yahoo.com - March 3 at 5:47 PMCytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbilfinance.yahoo.com - March 1 at 2:15 PMFDA Rejects Cytokinetics' Heart Failure Treatment Candidatefinance.yahoo.com - March 1 at 2:15 PMIs a Surprise Coming for Cytokinetics (CYTK) This Earnings Season?finance.yahoo.com - February 28 at 12:12 PMCytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Sessionfinance.yahoo.com - February 24 at 5:18 PMCytokinetics to Announce Fourth Quarter Results on March 1, 2023finance.yahoo.com - February 15 at 8:57 PMCytokinetics Announces Recipients of Its Fifth Annual Communications Grant Programfinance.yahoo.com - January 30 at 9:19 AMInvesting in Cytokinetics (NASDAQ:CYTK) five years ago would have delivered you a 369% gainfinance.yahoo.com - January 25 at 7:04 AMAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Maravai Lifesciences Holdings (MRVI)markets.businessinsider.com - January 17 at 12:58 PMCytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 13 at 3:32 PMCytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 8:07 PMMizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)markets.businessinsider.com - December 30 at 12:47 PMNewsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecastsfinance.yahoo.com - December 15 at 12:27 PMCytokinetics (CYTK) Up Despite Unfavorable FDA Committee Votingfinance.yahoo.com - December 15 at 12:27 PMCytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Saidfinance.yahoo.com - December 14 at 3:21 PMWhy Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drugfinance.yahoo.com - December 14 at 10:21 AMCytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbilfinance.yahoo.com - December 13 at 8:31 PMCytokinetics Stock Trading Halted Todayfinance.yahoo.com - December 13 at 9:14 AMCytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbilfinance.yahoo.com - December 9 at 5:36 PMCytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MNDfinance.yahoo.com - December 8 at 9:32 AMCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136finance.yahoo.com - December 7 at 1:03 PMCytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MNDfinance.yahoo.com - December 1 at 6:34 PMCytokinetics Third Quarter 2022 Earnings: Misses Expectationsfinance.yahoo.com - November 8 at 8:51 AMCytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022finance.yahoo.com - November 7 at 5:28 PMCytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022finance.yahoo.com - October 31 at 10:41 AMCytokinetics: 2 Catalysts For Heart Failure Drug Make This Worth A Lookseekingalpha.com - October 26 at 6:01 AMCytokinetics CEO: Why It's OK Not Being An Overnight Successfinance.yahoo.com - October 25 at 2:59 PMCytokinetics to Announce Third Quarter Results on November 3, 2022finance.yahoo.com - October 20 at 6:27 PMIs Cytokinetics (CYTK) a Good Long-Term Investment?finance.yahoo.com - October 18 at 2:58 PMCytokinetics: Surprise Adcomm For Omecamtiv Causing Concern (NASDAQ:CYTK) - Seeking Alphaseekingalpha.com - October 17 at 11:37 AMIs Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year? - Nasdaqnasdaq.com - October 14 at 11:16 AMNovartis to cut its Irish workforce by up to 25% - Yahoo Financefinance.yahoo.com - October 13 at 3:25 PMCytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis - Yahoo Financefinance.yahoo.com - October 12 at 6:19 PMCytokinetics (CYTK) to Continue ALS Study on Reldesemtivfinance.yahoo.com - October 11 at 4:06 PMWhere Cytokinetics Stands With Analysts - Cytokinetics (NASDAQ:CYTK) - Benzingabenzinga.com - October 11 at 11:06 AMCytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis - GlobeNewswireglobenewswire.com - October 10 at 8:34 AMCytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysisfinance.yahoo.com - October 10 at 8:34 AMIJR, LTHM, EXLS, CYTK: Large Outflows Detected at ETF - Nasdaqnasdaq.com - October 5 at 12:37 PMCoca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% By Benzinga - Investing.com UKuk.investing.com - October 3 at 1:33 PMCytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting - GlobeNewswireglobenewswire.com - October 2 at 12:32 PMCytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meetingfinance.yahoo.com - October 2 at 12:32 PMCytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions - GlobeNewswireglobenewswire.com - September 30 at 3:00 PMCytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessionsfinance.yahoo.com - September 30 at 3:00 PMCytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program - GlobeNewswireglobenewswire.com - September 28 at 7:55 AMCytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Programfinance.yahoo.com - September 28 at 7:55 AMCytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting - Yahoo Financefinance.yahoo.com - September 26 at 8:06 PM Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:CYTK) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.